TX-MOGAS-INDUSTRIES
18.5.2023 05:34:29 CEST | Business Wire | Press release
MOGAS Industries, Inc. (MOGAS) will be celebrating its 50-year anniversary with a commemorative celebration on Thursday, May 18th, 2023. The company officially began at 8:20 p.m. on May 17th, 1973.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230517005845/en/
Matt Mogas (left) and Louis Mogas (right) pose next to a large MOGAS ball valve (Photo: Business Wire)
MOGAS has earned a global reputation as a leading severe service manufacturer for the most extreme industrial applications in power, mining, refining, petrochemical/chemical, oil & gas, and specialty application industries. Significant business units include Severe Service Valves, Systems & Consulting (modules), Surface Technologies (coatings), Service & Reliability.
Louis Mogas formed Mogas Machine Works in 1973 with 16 employees working under 19,000 sq ft of manufacturing space on a couple of acres. Today, privately owned MOGAS Industries employs over 325 people across six countries. Their Houston-based headquarters now has 100,000 sq ft of manufacturing capacity spanning 15 acres. Campus improvements, such as 'Class A' corporate offices, an advanced coating facility, a 3-acre wooded park and numerous facility upgrades attest to MOGAS' success—not only as a significant manufacturer—but also to the Company staying true to its original business philosophy of putting people before profits.
A significant part of MOGAS sales is international, with sales and service centers in China, Australia, Canada, South America, Africa, The Middle East, Europe and India. With representatives and technicians in more than 40 countries, MOGAS is known for partnering with its customers to meet the ever-increasing challenges of severe-service applications.
On the occasion of the company’s 50th anniversary, MOGAS CEO/COO Matt Mogas notes: “I feel incredibly blessed to have worked with so many great employees, representatives, and customers these last 33 years. They have made a meaningful impact on MOGAS Industries and me personally. I feel honored to stand on the shoulders of the great men that came before me at MOGAS, especially Sam Furman, Tommy Bright, Cary Lorenz and of course my father, Louis Mogas, the grand architect, master, creator of our culture, beliefs and vision.”
Serving the community is ingrained in the MOGAS culture. The Company contributes significant resources to many worthy causes and enthusiastically supports their employees’ robust spirit of volunteerism. Charitable contributions to organizations include: Ronald McDonald House, MS150, Camp for All, The Periwinkle Foundation, and business partnerships with local elementary and junior schools. The Company also supports private initiatives for public good, focusing on quality of life.
The entire MOGAS organization is proud of this momentous achievement.
For more information, please contact MOGAS Industries at 281.449.0291 or Email: marketing@mogas.com
About MOGAS Industries, Inc.
MOGAS Industries Inc. is the most trusted severe service technology company, providing world-renowned services and the best severe service, application-specific products for critical applications in power, mining, oil & gas, refining, chemical/petrochemical and specialty industries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230517005845/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
IHS Towers Publishes 2025 Sustainability Report26.5.2026 12:34:00 CEST | Press release
IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom